FDA
-
-
-
-
-
-
-
ProstACT Global Phase 3 (Part 1) Data Presented in Late-Breaking Oral Session at ASCO 2026
-
-
-
-
-
-
-
FDA accepts Telix brain cancer imaging drug application
-
-
-
-
-
-
-
FY 2025 Results: Strong Commercial Growth, Focused Pipeline Investment
-
-
-
-
-
-
-
Precision Medicine Portfolio Update: Illuccix China Phase 3 Study, TLX101-CDx and TLX250-CDx FDA Resubmissions
-
-
-
-
-
-
-
CMS grants reimbursement status for Telix's Gozellix prostate imaging agent
-
-
-
-
-
-
-
Illuccix Approved in U.S. for Patient Selection for Pre-Taxane RLT
-
-
-
-
-
-
-
Telix Announces Cardinal Health for Gozellix Commercial Distribution
-
325,665 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

